SPOC Biosciences
SPOC Biosciences is a life sciences technology company focused on advancing proteomics through high-plex biosensor chip platforms. The company enables high-throughput, cost-effective protein production and deep characterization of protein interactions using techniques such as cell-free expression and multiplexed SPR biosensing. Their platform accelerates drug discovery, AI-driven drug design, biomarker identification, diagnostics, antibody screening, and vaccine development by generating scalable, high-resolution kinetic datasets suitable for advanced analytics and AI model training.
Industries
N/A
Nr. of Employees
small (1-50)
SPOC Biosciences
Products
Multiplexed protein biosensor chip platform
High-density biosensor chips for parallel production and kinetic profiling of hundreds to thousands of full-length proteins, compatible with surface plasmon resonance and mass spectrometry.
SPR assay suite for drug discovery (HyperKinetiKx/HyperSynaptiKx)
Suite of high-throughput surface plasmon resonance workflows for kinetic screening, affinity ranking, and epitope mapping of antibodies, proteins, and drug candidates.
Early Access Program for custom proteomic workflows
Pilot project engagements for AI-aided drug discovery partners to access proprietary high-throughput kinetic characterization and data generation.
Multiplexed protein biosensor chip platform
High-density biosensor chips for parallel production and kinetic profiling of hundreds to thousands of full-length proteins, compatible with surface plasmon resonance and mass spectrometry.
SPR assay suite for drug discovery (HyperKinetiKx/HyperSynaptiKx)
Suite of high-throughput surface plasmon resonance workflows for kinetic screening, affinity ranking, and epitope mapping of antibodies, proteins, and drug candidates.
Early Access Program for custom proteomic workflows
Pilot project engagements for AI-aided drug discovery partners to access proprietary high-throughput kinetic characterization and data generation.
Services
Provision of proprietary, high-resolution drug–target interaction and kinetic datasets for machine learning development and benchmarking.
In vitro validation of AI-generated drug molecules against protein targets, including kinetic, affinity, and selectivity profiling.
Screening of patient sera or plasma against produced proteomes for quantitative and kinetic immune response profiling.
Provision of proprietary, high-resolution drug–target interaction and kinetic datasets for machine learning development and benchmarking.
In vitro validation of AI-generated drug molecules against protein targets, including kinetic, affinity, and selectivity profiling.
Screening of patient sera or plasma against produced proteomes for quantitative and kinetic immune response profiling.
Expertise Areas
- Proteomics
- Protein production and engineering
- Surface plasmon resonance analytics
- Antibody discovery and optimization
Key Technologies
- Cell-free protein synthesis
- Surface plasmon resonance (SPR) biosensing
- Multiplexed biosensor chip technology
- MALDI-TOF mass spectrometry
News & Updates
An open challenge where participants use AI models to improve antibody binding affinity or pH responsiveness, driven by high-resolution kinetic datasets generated with the company's proprietary SPR platform.
Launching the Early Access Program for select pilot projects focused on AI-aided drug discovery and generation of proprietary data for AI model training.
Overview of how the nano-factory technology enables high-throughput, cost-effective protein production on biosensor chips.
Insight into the use of biosensor chip technology for high-plex protein production to support scalable proteomics.
Discussion on scalable protein production technologies and their impact on modern proteomics.
External review of low-plex proteomics and scalable protein production utilizing biosensor chips.
An open challenge where participants use AI models to improve antibody binding affinity or pH responsiveness, driven by high-resolution kinetic datasets generated with the company's proprietary SPR platform.
Launching the Early Access Program for select pilot projects focused on AI-aided drug discovery and generation of proprietary data for AI model training.
Overview of how the nano-factory technology enables high-throughput, cost-effective protein production on biosensor chips.
Insight into the use of biosensor chip technology for high-plex protein production to support scalable proteomics.
Discussion on scalable protein production technologies and their impact on modern proteomics.
External review of low-plex proteomics and scalable protein production utilizing biosensor chips.